Related Experiment Video
Updated: Jul 8, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Updates in management of cardiorenal syndrome
Isaac Chung1,2, Mimi Chen1,2, Lisa Anderson1,2
1St George's University Hospitals NHS Foundation Trust London.
Insights
Novel therapies are emerging for cardiorenal syndrome, a condition affecting frail, elderly patients. These treatments aim to improve quality of life and outcomes for individuals with cardiorenal syndrome across all stages of chronic kidney disease.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Cardiorenal syndrome is increasingly prevalent, linked to obesity, diabetes, and hypertension.
- It significantly impacts patient quality of life, leading to hospitalizations and mortality.
- Despite available evidence-based treatments, implementation remains a significant challenge.
Purpose of the Study:
- To review emerging evidence-based therapies for cardiorenal syndrome.
- To discuss challenges in managing cardiorenal syndrome across different patient populations.
- To highlight advancements in improving patient outcomes and quality of life.
Main Methods:
- Review of recent evidence-based therapies for cardiorenal syndrome.
- Discussion of management strategies for ambulatory and admitted patients.
- Analysis of challenges including electrolyte imbalance and diuretic resistance.
Main Results:
- Emerging therapies include nonsteroidal mineralocorticoid antagonists and glucagon-like peptide-1 receptor agonists for ambulatory patients.
- Management of admitted patients focuses on volume status optimization and overcoming diuretic resistance.
- New treatments offer greater flexibility in managing cardiorenal syndrome.
Conclusions:
- Novel therapies are expanding treatment options for cardiorenal syndrome.
- These advancements provide opportunities to improve patient outcomes and quality of life.
- Flexible management strategies are crucial for addressing cardiorenal syndrome spectrum.
Purpose Of Review:
Cardiorenal syndrome is common, increasing in prevalence mainly due to increases in obesity, diabetes, hypertension and chronic kidney disease. The patients with cardiorenal syndrome are often frail and elderly suffering from poor quality of life, multiple hospital admissions, and death. There has been an increase in the number of evidence-based medications available for prevention and treatment of cardiorenal syndrome; however, implementation remains a challenge.
Recent Findings:
In ambulatory patients, we discuss emerging evidence-based therapies such as nonsteroidal mineralocorticoid antagonists and glucagon-like peptide-1 receptor agonists for cardiorenal syndrome across all stages of chronic kidney disease, alongside the challenges of electrolyte imbalance and kidney function decline. In admitted patients, recent advances focus on optimization of volume status, including saline replacement during diuresis when appropriate and the use of adjuncts to loop diuretics (e.g. thiazide-type diuretics) to overcome diuretic resistance.
Summary:
These findings highlight the growing range of novel therapies expanding the cardiorenal physician's armamentarium, offering greater flexibility in managing cardiorenal syndrome across its spectrum to improve outcomes and improve the quality of life of patients suffering from cardiorenal syndrome.
Related Concept Videos
01:22Acute Kidney Injury VI: Nursing Management
01:20Acute Kidney Injury V: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:22Heart Failure Drugs: Diuretics